Carregant...
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...
Guardat en:
| Publicat a: | Ther Adv Neurol Disord |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222235/ https://ncbi.nlm.nih.gov/pubmed/32426040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420918088 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|